Intra-Cellular Therapies SWOT analysis CAPLYTA drives stock potential amid patent challenges
ITCI Stock | USD 82.56 0.67 0.80% |
Under 56% of Intracellular's investor base is looking to short. The analysis of overall sentiment of trading Intracellular Th stock suggests that many investors are alarmed at this time. Intracellular's investing sentiment shows overall attitude of investors towards Intracellular Th.
Intracellular |
Intra-Cellular Therapies SWOT analysis CAPLYTA drives stock potential amid patent challenges
Read at investing.com
Intracellular Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Intracellular can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Intracellular Maximum Pain Price Across January 17th 2025 Option Contracts
Intracellular's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Intracellular close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Intracellular's options.
Intracellular Fundamental Analysis
We analyze Intracellular's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intracellular using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intracellular based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
Intracellular is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Intracellular Th Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Intracellular stock to make a market-neutral strategy. Peer analysis of Intracellular could also be used in its relative valuation, which is a method of valuing Intracellular by comparing valuation metrics with similar companies.
Peers
Intracellular Related Equities
COLL | Collegium Pharmaceutical | 14.41 | ||||
CYTH | Cyclo Therapeutics | 6.15 | ||||
AMPH | Amphastar | 3.91 | ||||
AMRX | Amneal Pharmaceuticals, | 2.41 | ||||
IRWD | Ironwood Pharmaceuticals | 1.10 | ||||
NBIX | Neurocrine Biosciences | 0.84 | ||||
ANIP | ANI Pharmaceuticals | 0.40 | ||||
ALKS | Alkermes Plc | 0.42 | ||||
PCRX | Pacira BioSciences, | 0.54 | ||||
DVAX | Dynavax Technologies | 1.64 | ||||
AQST | Aquestive Therapeutics | 2.80 |
Complementary Tools for Intracellular Stock analysis
When running Intracellular's price analysis, check to measure Intracellular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intracellular is operating at the current time. Most of Intracellular's value examination focuses on studying past and present price action to predict the probability of Intracellular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intracellular's price. Additionally, you may evaluate how the addition of Intracellular to your portfolios can decrease your overall portfolio volatility.
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |